APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease

被引:36
|
作者
Sun, Xiaoyan [1 ,2 ]
Dong, Chuanhui [1 ,2 ]
Levin, Bonnie [1 ,2 ]
Crocco, Elizabeth [3 ]
Loewenstein, David [3 ]
Zetterberg, Henrik [4 ,5 ,6 ]
Blennow, Kaj [4 ,6 ]
Wright, Clinton B. [1 ,2 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Evelyn F McKnight Brain Inst, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL 33136 USA
[4] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
[5] UCL Inst Neurol, Dept Mol Neurosci, London, England
[6] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Synaptic function; Neurogranin; APOE epsilon 4; Alzheimer's disease; APOE; Mild cognitive impairment; CEREBROSPINAL-FLUID BIOMARKER; APOLIPOPROTEIN-E; AMYLOID-BETA; PROTEIN; NEUROGRANIN; PLASTICITY; MICE; TAU; DYSFUNCTION; OLIGOMERS;
D O I
10.1016/j.jalz.2016.05.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Pathogenesis of Alzheimer's disease (AD) in apolipoprotein E epsilon 4 (APOE epsilon 4) carriers remains unclear. We hypothesize that APOE isoforms have differential effects on synaptic function. Methods: We compared levels of CSF neurogranin (Ng) between APOE epsilon 4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF-A beta 42, and tau protein. Results: Neurogranin levels were significantly higher in APOE epsilon 4 carriers compared to APOE epsilon 4 noncarriers with MCI. Levels of Ng between the APOE epsilon 4 carriers and APOE 64 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and A beta 42. Discussion: Significantly higher CSF Ng levels in APOE epsilon 4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE epsilon 4 carriers. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 50 条
  • [1] Refining Risk for Alzheimer's Disease Among Heterozygous APOE ε4 Carriers
    Patel, Smita
    Wei, Jun
    Shi, Zhuqing
    Rifkin, Andrew S.
    Zheng, S. Lilly
    Gelfman, Elizabeth
    Duggan, David
    Helfand, Brian T.
    Hulick, Peter J.
    Xu, Jianfeng
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 94 (02) : 483 - 489
  • [2] mTOR: Alzheimer's disease prevention for APOE4 carriers
    Lin, Ai-Ling
    Butterfield, D. Allan
    Richardson, Arlan
    ONCOTARGET, 2016, 7 (29) : 44873 - 44874
  • [3] Cerebral microvascular changes in healthy carriers of the APOE-ε4 Alzheimer's disease risk gene
    Aamand, Rasmus
    Rasmussen, Peter M.
    Andersen, Katrine Schilling
    de Paoli, Stine
    Weitzberg, Eddie
    Christiansen, Michael
    Lund, Torben E.
    Ostergaard, Leif
    PNAS NEXUS, 2024, 3 (09):
  • [4] APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis
    Md. Sahab Uddin
    Md. Tanvir Kabir
    Abdullah Al Mamun
    Mohamed M. Abdel-Daim
    George E. Barreto
    Ghulam Md Ashraf
    Molecular Neurobiology, 2019, 56 : 2450 - 2465
  • [5] APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis
    Uddin, Md. Sahab
    Kabir, Md. Tanvir
    Al Mamun, Abdullah
    Abdel-Daim, Mohamed M.
    Barreto, George E.
    Ashraf, Ghulam Md
    MOLECULAR NEUROBIOLOGY, 2019, 56 (04) : 2450 - 2465
  • [6] The detrimental effects of APOE4 on risk for Alzheimer's disease may result from altered dendritic spine density, synaptic proteins, and
    Taxier, Lisa R.
    Philippi, Sarah M.
    York, Jason M.
    LaDu, Mary Jo
    Frick, Karyn M.
    NEUROBIOLOGY OF AGING, 2022, 112 : 74 - 86
  • [7] Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers
    Chetelat, G.
    Fouquet, M.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 729 - 736
  • [8] ApoE4: A RISK FACTOR FOR ALZHEIMER'S DISEASE
    Agarwala, A.
    Durakoglugil, M.
    Xian, D.
    Bowen, I
    Herz, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2011, 59 (02) : 469 - 469
  • [9] GAB2 gene does not modify the risk of Alzheimer’s disease in Spanish APOE 4 carriers
    Reposo Ramírez-Lorca
    M. Boada
    M. E. Saez
    I. Hernandez
    A. Mauleon
    M. Rosende-Roca
    P. Martinez-Lage
    M. Gutierrez
    L. M. Real
    J. Lopez-Arrieta
    J. Gayan
    C. Antunez
    A. Gonzalez-Perez
    L. Tarraga
    A. Ruiz
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 214 - 219
  • [10] GAB2 GENE DOES NOT MODIFY THE RISK OF ALZHEIMER'S DISEASE IN SPANISH APOE 4 CARRIERS
    Ramirez-Lorca, R.
    Boada, M.
    Saez, M. E.
    Hernandez, I.
    Mauleon, A.
    Rosende-Roca, M.
    Martinez-Lage, P.
    Gutierrez, M.
    Real, L. M.
    Lopez-Arrieta, J.
    Gayan, J.
    Antunez, C.
    Gonzalez-Perez, A.
    Tarraga, L.
    Ruiz, A.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (03): : 214 - 219